Loading…

The utility of methylmalonic acid, methylcitrate acid, and homocysteine in dried blood spots for therapeutic monitoring of three inherited metabolic diseases

Routine metabolic assessments for methylmalonic acidemia (MMA), propionic acidemia (PA), and homocysteinemia involve detecting metabolites in dried blood spots (DBS) and analyzing specific biomarkers in serum and urine. This study aimed to establish a liquid chromatography-tandem mass spectrometry (...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in nutrition (Lausanne) 2024-06, Vol.11, p.1414681
Main Authors: Liu, Yi, Ma, Xue, Kang, Lulu, Jin, Ying, Li, Mengqiu, Song, Jinqing, Li, Haixia, Cao, Yongtong, Yang, Yanling
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c348t-eca7a61f5e3f9bd9aa84754c867e20922ffee48107ccd22613364fd113b7dae43
container_end_page
container_issue
container_start_page 1414681
container_title Frontiers in nutrition (Lausanne)
container_volume 11
creator Liu, Yi
Ma, Xue
Kang, Lulu
Jin, Ying
Li, Mengqiu
Song, Jinqing
Li, Haixia
Cao, Yongtong
Yang, Yanling
description Routine metabolic assessments for methylmalonic acidemia (MMA), propionic acidemia (PA), and homocysteinemia involve detecting metabolites in dried blood spots (DBS) and analyzing specific biomarkers in serum and urine. This study aimed to establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous detection of three specific biomarkers (methylmalonic acid, methylcitric acid, and homocysteine) in DBS, as well as to appraise the applicability of these three DBS metabolites in monitoring patients with MMA, PA, and homocysteinemia during follow-up. A total of 140 healthy controls and 228 participants were enrolled, including 205 patients with MMA, 17 patients with PA, and 6 patients with homocysteinemia. Clinical data and DBS samples were collected during follow-up visits. The reference ranges (25th-95th percentile) for DBS methylmalonic acid, methylcitric acid, and homocysteine were estimated as 0.04-1.02 μmol/L, 0.02-0.27 μmol/L and 1.05-8.22 μmol/L, respectively. Following treatment, some patients achieved normal metabolite concentrations, but the majority still exhibited characteristic biochemical patterns. The concentrations of methylmalonic acid, methylcitric acid, and homocysteine in DBS showed positive correlations with urine methylmalonic acid (  = 0.849,  
doi_str_mv 10.3389/fnut.2024.1414681
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_48451d7b57be459ebffe7f4ce57f1851</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_48451d7b57be459ebffe7f4ce57f1851</doaj_id><sourcerecordid>3076019907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-eca7a61f5e3f9bd9aa84754c867e20922ffee48107ccd22613364fd113b7dae43</originalsourceid><addsrcrecordid>eNpVks1u1DAUhSMEolXpA7BBXrJgBv_FdlYIVdBWqsSmSOwsx76euEriwfYgzcP0XXGYULUrWzfnfMexT9O8J3jLmOo--_lQthRTviWccKHIq-ac0k5slCC_Xj_bnzWXOT9gjAmjbZW-bc6qXwhO2HnzeD8AOpQwhnJE0aMJynAcJzPGOVhkbHCf1pkNJZkC68zMDg1xivaYC4QZUJiRSwEc6scYHcr7WDLyMaEyQDJ7qBkWTZVaYgrzbskqQ4LFWAWhVGfNMX0cq86FDCZDfte88WbMcLmuF83P79_ur242dz-ub6--3m0s46pswBppBPEtMN_1rjNGcdlyq4QEijtKvQfgimBpraNUEMYE944Q1ktngLOL5vbEddE86H0Kk0lHHU3Q_wYx7bRJ9QdG0FzxljjZt7IH3nbQV7b03EIrPVEtqawvJ9b-0E_gLMz13sYX0Jdf5jDoXfyjCaH1zZSshI8rIcXfB8hFTyFbGEczQzxkzbAUmHQdXqTkJLUp5pzAP-UQrJea6KUmeqmJXmtSPR-eH_DJ8b8U7C8JkL77</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3076019907</pqid></control><display><type>article</type><title>The utility of methylmalonic acid, methylcitrate acid, and homocysteine in dried blood spots for therapeutic monitoring of three inherited metabolic diseases</title><source>PubMed</source><creator>Liu, Yi ; Ma, Xue ; Kang, Lulu ; Jin, Ying ; Li, Mengqiu ; Song, Jinqing ; Li, Haixia ; Cao, Yongtong ; Yang, Yanling</creator><creatorcontrib>Liu, Yi ; Ma, Xue ; Kang, Lulu ; Jin, Ying ; Li, Mengqiu ; Song, Jinqing ; Li, Haixia ; Cao, Yongtong ; Yang, Yanling</creatorcontrib><description>Routine metabolic assessments for methylmalonic acidemia (MMA), propionic acidemia (PA), and homocysteinemia involve detecting metabolites in dried blood spots (DBS) and analyzing specific biomarkers in serum and urine. This study aimed to establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous detection of three specific biomarkers (methylmalonic acid, methylcitric acid, and homocysteine) in DBS, as well as to appraise the applicability of these three DBS metabolites in monitoring patients with MMA, PA, and homocysteinemia during follow-up. A total of 140 healthy controls and 228 participants were enrolled, including 205 patients with MMA, 17 patients with PA, and 6 patients with homocysteinemia. Clinical data and DBS samples were collected during follow-up visits. The reference ranges (25th-95th percentile) for DBS methylmalonic acid, methylcitric acid, and homocysteine were estimated as 0.04-1.02 μmol/L, 0.02-0.27 μmol/L and 1.05-8.22 μmol/L, respectively. Following treatment, some patients achieved normal metabolite concentrations, but the majority still exhibited characteristic biochemical patterns. The concentrations of methylmalonic acid, methylcitric acid, and homocysteine in DBS showed positive correlations with urine methylmalonic acid (  = 0.849,  &lt; 0.001), urine methylcitric acid (  = 0.693,  &lt; 0.001), and serum homocysteine (  = 0.721,  &lt; 0.001) concentrations, respectively. Additionally, higher levels of DBS methylmalonic acid and methylcitric acid may be associated with increased cumulative complication scores. The LC-MS/MS method established in this study reliably detects methylmalonic acid, methylcitric acid, and homocysteine in DBS. These three DBS metabolites can be valuable for monitoring patients with MMA, PA, and homocysteinemia during follow-up. Further investigation is required to determine the significance of these DBS biomarkers in assessing disease burden over time.</description><identifier>ISSN: 2296-861X</identifier><identifier>EISSN: 2296-861X</identifier><identifier>DOI: 10.3389/fnut.2024.1414681</identifier><identifier>PMID: 38966413</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>homocysteine ; homocystinemia ; inherited metabolic disease ; metabolic evaluation ; methylcitric acid ; methylmalonic acid ; Nutrition</subject><ispartof>Frontiers in nutrition (Lausanne), 2024-06, Vol.11, p.1414681</ispartof><rights>Copyright © 2024 Liu, Ma, Kang, Jin, Li, Song, Li, Cao and Yang.</rights><rights>Copyright © 2024 Liu, Ma, Kang, Jin, Li, Song, Li, Cao and Yang. 2024 Liu, Ma, Kang, Jin, Li, Song, Li, Cao and Yang</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c348t-eca7a61f5e3f9bd9aa84754c867e20922ffee48107ccd22613364fd113b7dae43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222987/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11222987/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38966413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Yi</creatorcontrib><creatorcontrib>Ma, Xue</creatorcontrib><creatorcontrib>Kang, Lulu</creatorcontrib><creatorcontrib>Jin, Ying</creatorcontrib><creatorcontrib>Li, Mengqiu</creatorcontrib><creatorcontrib>Song, Jinqing</creatorcontrib><creatorcontrib>Li, Haixia</creatorcontrib><creatorcontrib>Cao, Yongtong</creatorcontrib><creatorcontrib>Yang, Yanling</creatorcontrib><title>The utility of methylmalonic acid, methylcitrate acid, and homocysteine in dried blood spots for therapeutic monitoring of three inherited metabolic diseases</title><title>Frontiers in nutrition (Lausanne)</title><addtitle>Front Nutr</addtitle><description>Routine metabolic assessments for methylmalonic acidemia (MMA), propionic acidemia (PA), and homocysteinemia involve detecting metabolites in dried blood spots (DBS) and analyzing specific biomarkers in serum and urine. This study aimed to establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous detection of three specific biomarkers (methylmalonic acid, methylcitric acid, and homocysteine) in DBS, as well as to appraise the applicability of these three DBS metabolites in monitoring patients with MMA, PA, and homocysteinemia during follow-up. A total of 140 healthy controls and 228 participants were enrolled, including 205 patients with MMA, 17 patients with PA, and 6 patients with homocysteinemia. Clinical data and DBS samples were collected during follow-up visits. The reference ranges (25th-95th percentile) for DBS methylmalonic acid, methylcitric acid, and homocysteine were estimated as 0.04-1.02 μmol/L, 0.02-0.27 μmol/L and 1.05-8.22 μmol/L, respectively. Following treatment, some patients achieved normal metabolite concentrations, but the majority still exhibited characteristic biochemical patterns. The concentrations of methylmalonic acid, methylcitric acid, and homocysteine in DBS showed positive correlations with urine methylmalonic acid (  = 0.849,  &lt; 0.001), urine methylcitric acid (  = 0.693,  &lt; 0.001), and serum homocysteine (  = 0.721,  &lt; 0.001) concentrations, respectively. Additionally, higher levels of DBS methylmalonic acid and methylcitric acid may be associated with increased cumulative complication scores. The LC-MS/MS method established in this study reliably detects methylmalonic acid, methylcitric acid, and homocysteine in DBS. These three DBS metabolites can be valuable for monitoring patients with MMA, PA, and homocysteinemia during follow-up. Further investigation is required to determine the significance of these DBS biomarkers in assessing disease burden over time.</description><subject>homocysteine</subject><subject>homocystinemia</subject><subject>inherited metabolic disease</subject><subject>metabolic evaluation</subject><subject>methylcitric acid</subject><subject>methylmalonic acid</subject><subject>Nutrition</subject><issn>2296-861X</issn><issn>2296-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVks1u1DAUhSMEolXpA7BBXrJgBv_FdlYIVdBWqsSmSOwsx76euEriwfYgzcP0XXGYULUrWzfnfMexT9O8J3jLmOo--_lQthRTviWccKHIq-ac0k5slCC_Xj_bnzWXOT9gjAmjbZW-bc6qXwhO2HnzeD8AOpQwhnJE0aMJynAcJzPGOVhkbHCf1pkNJZkC68zMDg1xivaYC4QZUJiRSwEc6scYHcr7WDLyMaEyQDJ7qBkWTZVaYgrzbskqQ4LFWAWhVGfNMX0cq86FDCZDfte88WbMcLmuF83P79_ur242dz-ub6--3m0s46pswBppBPEtMN_1rjNGcdlyq4QEijtKvQfgimBpraNUEMYE944Q1ktngLOL5vbEddE86H0Kk0lHHU3Q_wYx7bRJ9QdG0FzxljjZt7IH3nbQV7b03EIrPVEtqawvJ9b-0E_gLMz13sYX0Jdf5jDoXfyjCaH1zZSshI8rIcXfB8hFTyFbGEczQzxkzbAUmHQdXqTkJLUp5pzAP-UQrJea6KUmeqmJXmtSPR-eH_DJ8b8U7C8JkL77</recordid><startdate>20240620</startdate><enddate>20240620</enddate><creator>Liu, Yi</creator><creator>Ma, Xue</creator><creator>Kang, Lulu</creator><creator>Jin, Ying</creator><creator>Li, Mengqiu</creator><creator>Song, Jinqing</creator><creator>Li, Haixia</creator><creator>Cao, Yongtong</creator><creator>Yang, Yanling</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240620</creationdate><title>The utility of methylmalonic acid, methylcitrate acid, and homocysteine in dried blood spots for therapeutic monitoring of three inherited metabolic diseases</title><author>Liu, Yi ; Ma, Xue ; Kang, Lulu ; Jin, Ying ; Li, Mengqiu ; Song, Jinqing ; Li, Haixia ; Cao, Yongtong ; Yang, Yanling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-eca7a61f5e3f9bd9aa84754c867e20922ffee48107ccd22613364fd113b7dae43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>homocysteine</topic><topic>homocystinemia</topic><topic>inherited metabolic disease</topic><topic>metabolic evaluation</topic><topic>methylcitric acid</topic><topic>methylmalonic acid</topic><topic>Nutrition</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Yi</creatorcontrib><creatorcontrib>Ma, Xue</creatorcontrib><creatorcontrib>Kang, Lulu</creatorcontrib><creatorcontrib>Jin, Ying</creatorcontrib><creatorcontrib>Li, Mengqiu</creatorcontrib><creatorcontrib>Song, Jinqing</creatorcontrib><creatorcontrib>Li, Haixia</creatorcontrib><creatorcontrib>Cao, Yongtong</creatorcontrib><creatorcontrib>Yang, Yanling</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in nutrition (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Yi</au><au>Ma, Xue</au><au>Kang, Lulu</au><au>Jin, Ying</au><au>Li, Mengqiu</au><au>Song, Jinqing</au><au>Li, Haixia</au><au>Cao, Yongtong</au><au>Yang, Yanling</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The utility of methylmalonic acid, methylcitrate acid, and homocysteine in dried blood spots for therapeutic monitoring of three inherited metabolic diseases</atitle><jtitle>Frontiers in nutrition (Lausanne)</jtitle><addtitle>Front Nutr</addtitle><date>2024-06-20</date><risdate>2024</risdate><volume>11</volume><spage>1414681</spage><pages>1414681-</pages><issn>2296-861X</issn><eissn>2296-861X</eissn><abstract>Routine metabolic assessments for methylmalonic acidemia (MMA), propionic acidemia (PA), and homocysteinemia involve detecting metabolites in dried blood spots (DBS) and analyzing specific biomarkers in serum and urine. This study aimed to establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous detection of three specific biomarkers (methylmalonic acid, methylcitric acid, and homocysteine) in DBS, as well as to appraise the applicability of these three DBS metabolites in monitoring patients with MMA, PA, and homocysteinemia during follow-up. A total of 140 healthy controls and 228 participants were enrolled, including 205 patients with MMA, 17 patients with PA, and 6 patients with homocysteinemia. Clinical data and DBS samples were collected during follow-up visits. The reference ranges (25th-95th percentile) for DBS methylmalonic acid, methylcitric acid, and homocysteine were estimated as 0.04-1.02 μmol/L, 0.02-0.27 μmol/L and 1.05-8.22 μmol/L, respectively. Following treatment, some patients achieved normal metabolite concentrations, but the majority still exhibited characteristic biochemical patterns. The concentrations of methylmalonic acid, methylcitric acid, and homocysteine in DBS showed positive correlations with urine methylmalonic acid (  = 0.849,  &lt; 0.001), urine methylcitric acid (  = 0.693,  &lt; 0.001), and serum homocysteine (  = 0.721,  &lt; 0.001) concentrations, respectively. Additionally, higher levels of DBS methylmalonic acid and methylcitric acid may be associated with increased cumulative complication scores. The LC-MS/MS method established in this study reliably detects methylmalonic acid, methylcitric acid, and homocysteine in DBS. These three DBS metabolites can be valuable for monitoring patients with MMA, PA, and homocysteinemia during follow-up. Further investigation is required to determine the significance of these DBS biomarkers in assessing disease burden over time.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>38966413</pmid><doi>10.3389/fnut.2024.1414681</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2296-861X
ispartof Frontiers in nutrition (Lausanne), 2024-06, Vol.11, p.1414681
issn 2296-861X
2296-861X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_48451d7b57be459ebffe7f4ce57f1851
source PubMed
subjects homocysteine
homocystinemia
inherited metabolic disease
metabolic evaluation
methylcitric acid
methylmalonic acid
Nutrition
title The utility of methylmalonic acid, methylcitrate acid, and homocysteine in dried blood spots for therapeutic monitoring of three inherited metabolic diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T01%3A40%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20utility%20of%20methylmalonic%20acid,%20methylcitrate%20acid,%20and%20homocysteine%20in%20dried%20blood%20spots%20for%20therapeutic%20monitoring%20of%20three%20inherited%20metabolic%20diseases&rft.jtitle=Frontiers%20in%20nutrition%20(Lausanne)&rft.au=Liu,%20Yi&rft.date=2024-06-20&rft.volume=11&rft.spage=1414681&rft.pages=1414681-&rft.issn=2296-861X&rft.eissn=2296-861X&rft_id=info:doi/10.3389/fnut.2024.1414681&rft_dat=%3Cproquest_doaj_%3E3076019907%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c348t-eca7a61f5e3f9bd9aa84754c867e20922ffee48107ccd22613364fd113b7dae43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3076019907&rft_id=info:pmid/38966413&rfr_iscdi=true